THE Therapeutic Goods Administration (TGA) has approved six-in-one paediatric combination vaccine, Vaxelis.
The vaccine's active ingredients include, Diphtheria toxoid, Haemophilus influenza type B polyribose ribitol phosphate, hepatitis B surface antigen, Pertactin, Pertussis filamentous haemagglutinin, Pertussis fimbriae 2 3, Pertussis toxoid, Poliovirus and Tetanus toxoid.
The primary vaccination schedule consists of two to three doses, with an interval of at least a month between shots, and can be given from six weeks of age.
Where a dose of a hepatitis B vaccine has been given at birth, Vaxelis can be used for supplementary doses from six weeks of age.
CLICK HERE for more information .
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 22
